Page last updated: 2024-12-08
abt 491
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ABT 491: a highly potent platelet-activating factor receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 154086 |
SCHEMBL ID | 7943577 |
MeSH ID | M0278815 |
Synonyms (25)
Synonym |
---|
abt-491 hydrochloride, >=98% (hplc) |
abt-491 |
1h-indole-1-carboxamide, 4-ethynyl-3-(3-fluoro-4-((2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)methyl)benzoyl)-n,n-dimethyl-, monohydrochloride |
4-ethynyl-3-(3-fluoro-4-((2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)methyl)benzoyl)-n,n-dimethyl-1h-indole-1-carboxamide monohydrochloride |
abt 491 hydrochloride |
unii-n7ig7z867j |
4-ethynyl-n,n-dimethyl-3-(3-fluoro-4-((2-methyl-1h-imidazo-(4,5-c)pyridin-1-yl)methyl)benzoyl)-1h-indole-1-carboxamide hydrochloride |
n7ig7z867j , |
abt 491 |
4-ethynyl-n,n-dimethyl-3-[3-fluoro-4-[(2-methyl-1h-imidazo-[4,5-c]pyridin-1-yl)methyl]benzoyl]-1h-indole-1-carboxamide hydrochloride |
189689-94-9 |
abt-491 hydrochloride |
a-137491 |
AKOS015889278 |
methyl-1h-imidazo(4,5-c)pyridin-1-yl)methyl)benzoyl)-n,n-dimethyl-, hydrochloride |
(4-ethynyl-n,n-dimethyl-3-(3-fluoro-4-((2-methyl-1h-imidazo-(4,5-c)pyridin-1-yl)methyl)benzoyl)-1h-indole-1-carboxamide hydrochloride |
SCHEMBL7943577 |
DTXSID90172381 |
J-012241 |
4-ethynyl-3-(3-fluoro-4-((2-methyl-1h-imidazo[4,5-c]pyridin-1-yl)methyl)benzoyl)-n,n-dimethyl-1h-indole-1-carboxamide hydrochloride |
paf receptor antagonist, abt-491 - cas 189689-94-9 |
a 137491 |
4-ethynyl-3-[3-fluoro-4-[(2-methyl-3h-imidazo[4,5-c]pyridin-1-ium-1-yl)methyl]benzoyl]-n,n-dimethylindole-1-carboxamide;chloride |
4-ethynyl-3-[3-fluoro-4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]benzoyl]-n,n-dimethylindole-1-carboxamide;hydrochloride |
1h-indole-1-carboxamide, 4-ethynyl-3-[3-fluoro-4-[(2-methyl-1h-imidazo[4,5-c]pyridin-1-yl)methyl]benzoyl]-n,n-dimethyl-, hydrochloride (1:1) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (33.33) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.20) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |